Close
Almac
Achema middle east

South Australia Government Looks To Boost Biomanufacturing

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Redefining Success Metrics in Pharma Portfolio Management

Shift from traditional R&D metrics focused on milestone completion and budget adherence to outcome-based, value-focused metrics that measure strategic impact, learning velocity, and long-term portfolio health while aligning organizational behavior with strategic objectives.

Smarter Resource Planning for Complex Pharma Development Portfolios

Align limited resources with complex pharmaceutical portfolios through capacity forecasting, skills-based planning, and dynamic resource reallocation, improving execution outcomes without increasing costs or overburdening teams.

Samsung Biologics to Buy US Drug Plant from GSK for $280M

On December 22, 2025, the news has been confirmed...
- Advertisement -

Biomanufacturing industry is all set to get the much-needed push by the recent South Australian Government’s announcement when it comes to new initiatives as far as training and development of next generation researchers in this field are concerned.

This will help support the collaborations that the University of Adelaide already has with the sector partners. Apparently, a novel industry-linked initiative has been put in place as a part of the government’s Industry Doctoral Training Center push that brings together the universities of the state with numerous industry partners.

It is well to be noted that biomanufacturing is a kind of manufacturing or biotechnology that makes use of biological systems to commercially produce significant biomolecules and biomaterials for usage in medicine, industrial applications, as well as food and beverage processing. For instance, the University of Adelaide is collaborating with one of the companies that is into the manufacturing of next-generation vaccines. Apparently, the collaboration is going to be on a novel mRNA vaccine development that is not going to require any sort of ultracold storage or transportation, as confirmed by BioProcess Engineering professor from the University of Adelaide, Robert Falconer.

PhD students are going to be a part of the group, which will be working on projects that will be co-designed with the partners of the university and thereby offer peer-to-peer learning as well as mutual support.

They will have the opportunity to enhance their skills, which will in turn set them on a growth trajectory in their respective careers and also provide them with a wide range of opportunities simultaneously with specific doctoral trainings so as to develop contacts and also understand the sectors as well as business requirements. It has been decided that the PhD researchers will begin their training under the new initiative this year itself.

Latest stories

Related stories

Redefining Success Metrics in Pharma Portfolio Management

Shift from traditional R&D metrics focused on milestone completion and budget adherence to outcome-based, value-focused metrics that measure strategic impact, learning velocity, and long-term portfolio health while aligning organizational behavior with strategic objectives.

Smarter Resource Planning for Complex Pharma Development Portfolios

Align limited resources with complex pharmaceutical portfolios through capacity forecasting, skills-based planning, and dynamic resource reallocation, improving execution outcomes without increasing costs or overburdening teams.

Samsung Biologics to Buy US Drug Plant from GSK for $280M

On December 22, 2025, the news has been confirmed...

Maximizing Portfolio Returns During Late-Stage Drug Development

Optimize late-stage pharmaceutical assets through strategic investment planning, risk management, and indication prioritization. Maximize R&D return on investment during the highest-stakes phase of drug development.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »